CNMD logo

CNMDConmed Corp.

$34.65
$1.05
(2.94%)
Today
Closed $34.65
$0.00
(0.00%)
After Hours
Updated: 06:22 PM EDT
EarningsAug 5
Mkt Cap$1.07B
Vol525,131.00
News
all
press releases
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CNMD is sharpening its focus on AirSeal, Buffalo Filter and BioBrace, betting on higher-growth platforms to drive margin gains and long-term growth.
Zacks
News Placeholder
More News
News Placeholder
Why Is Conmed (CNMD) Down 3.1% Since Last Earnings Report?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Can CAH's Surging Other Growth Businesses Become Its Next Profit Engine?
CAH's fast-growing Other Growth Businesses posted 34% revenue growth and 52% profit gains, raising their role in long-term earnings.
Zacks
News Placeholder
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (Board), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the...
Business Wire
News Placeholder
Is the Options Market Predicting a Spike in CONMED Stock?
Investors need to pay close attention to CNMD stock based on the movements in the options market lately.
Zacks
News Placeholder
CONMED (NYSE:CNMD) Price Target Lowered to $39.00 at Wells Fargo & Company
Wells Fargo & Company reduced their target price on CONMED from $42.00 to $39.00 and set an "equal weight" rating on the stock in a research note on Friday...
MarketBeat
News Placeholder
CONMED (NYSE:CNMD) Price Target Lowered to $40.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co. lowered their price target on shares of CONMED from $43.00 to $40.00 and set a "neutral" rating on the stock in a report on Thursday...
MarketBeat
News Placeholder
CONMED's Q1 Earnings and Revenues Beat, Organic Sales Outlook Up
CNMD tops Q1 estimates despite sales dip, lifts 2026 organic growth outlook as strategic shift sharpens focus on higher-growth segments.
Zacks
News Placeholder
CONMED Q1 Earnings Call Highlights
CONMED (NYSE:CNMD) executives told investors the company is sharpening its focus on higher-growth, higher-margin platforms after reaching agreements to divest its gastroenterology (GI) product lines...
MarketBeat
News Placeholder
CONMED (NYSE:CNMD) Releases Earnings Results, Beats Estimates By $0.07 EPS
CONMED (NYSE:CNMD - Get Free Report) released its quarterly earnings results on Wednesday. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.82 by...
MarketBeat
<
1
2
...
>